NO20044947L - MUC-1 antigen med redusert antall VNTR gjentagene enheter - Google Patents

MUC-1 antigen med redusert antall VNTR gjentagene enheter

Info

Publication number
NO20044947L
NO20044947L NO20044947A NO20044947A NO20044947L NO 20044947 L NO20044947 L NO 20044947L NO 20044947 A NO20044947 A NO 20044947A NO 20044947 A NO20044947 A NO 20044947A NO 20044947 L NO20044947 L NO 20044947L
Authority
NO
Norway
Prior art keywords
muc
nucleic acid
repeating units
pharmaceutical compositions
vntr
Prior art date
Application number
NO20044947A
Other languages
English (en)
Other versions
NO20044947D0 (no
Inventor
Jonathan Henry Ellis
Neil Burden
Paul A Hamblin
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20044947D0 publication Critical patent/NO20044947D0/no
Publication of NO20044947L publication Critical patent/NO20044947L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Foreliggende oppfinnelse angår nye nukleinsyrekonstruksjoner, nyttige i fremgangsmåter for nukleisyrevaksinering for behandling og profylakse av MUC-1 - uttrykkende tumorer. Spesielt er nukleinsyren DNA og DNA-konstruksjonene omfatter et gen som koder for et MUC-1-derivat som har mindre enn 10 perfekt repeterte enheter. Oppfinnelsen tilveiebringer videre farmasøytiske sammensetninger omfattende nevnte konstruksjoner, spesielt farmasøytiske sammensetninger egnet for partikkelmediert levering, fremgangsmåter for fremstilling av dem, og deres anvendelse i medisin. Nye proteiner som kodes for av nukleinsyren og farmasøytiske sammensetninger som inneholder dem tilveiebringes også.
NO20044947A 2002-05-24 2004-11-12 MUC-1 antigen med redusert antall VNTR gjentagene enheter NO20044947L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0212046.7A GB0212046D0 (en) 2002-05-24 2002-05-24 Vaccines
PCT/EP2003/005594 WO2003100060A2 (en) 2002-05-24 2003-05-23 Muc-1 antigen with reduced number of vntr repeat units

Publications (2)

Publication Number Publication Date
NO20044947D0 NO20044947D0 (no) 2004-11-12
NO20044947L true NO20044947L (no) 2005-12-16

Family

ID=9937394

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20044947A NO20044947L (no) 2002-05-24 2004-11-12 MUC-1 antigen med redusert antall VNTR gjentagene enheter

Country Status (20)

Country Link
US (1) US20060251665A1 (no)
EP (1) EP1527177A2 (no)
JP (1) JP2005526520A (no)
KR (1) KR20050004211A (no)
CN (1) CN100408682C (no)
AR (1) AR039846A1 (no)
AU (1) AU2003240729B2 (no)
BR (1) BR0311211A (no)
CA (1) CA2485816A1 (no)
GB (1) GB0212046D0 (no)
IL (1) IL165156A0 (no)
IS (1) IS7526A (no)
MX (1) MXPA04011527A (no)
NO (1) NO20044947L (no)
NZ (1) NZ536668A (no)
PL (1) PL374569A1 (no)
RU (1) RU2303069C2 (no)
TW (1) TW200407426A (no)
WO (1) WO2003100060A2 (no)
ZA (1) ZA200409445B (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0212036D0 (en) * 2002-05-24 2002-07-03 Glaxo Group Ltd Vaccines
GB0304634D0 (en) * 2003-02-28 2003-04-02 Glaxo Group Ltd Vaccines
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
US8901093B2 (en) 2003-11-12 2014-12-02 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Custom vectors for treating and preventing pancreatic cancer
WO2005046614A2 (en) * 2003-11-12 2005-05-26 Therion Biologics Corporation System for treating and preventing breast cancer
ATE527285T1 (de) * 2005-01-28 2011-10-15 Univ Ramot Anti-muc1-alpha-beta-antikörper
US20120039984A1 (en) 2008-07-03 2012-02-16 University Of Georgia Research Foundation, Inc. Glycopeptide and uses thereof
CN106215179A (zh) * 2010-06-11 2016-12-14 乔治亚大学研究基金公司 免疫原性疫苗
CN103209701B (zh) * 2010-06-11 2016-08-03 乔治亚大学研究基金公司 免疫原性疫苗
CN105193724A (zh) * 2011-02-24 2015-12-30 肿瘤防护公司 含有佐剂的以muc1 为基础的糖脂肽疫苗
ES2811523T3 (es) * 2016-01-19 2021-03-12 Pfizer Vacunas contra el cáncer
EP3518964A2 (en) 2016-09-28 2019-08-07 Bavarian Nordic A/S Compositions and methods for enhancing the stability of transgenes in poxviruses
HRP20240756T1 (hr) 2018-05-18 2024-09-13 Daiichi Sankyo Co., Ltd. Anti-muc1-eksatekan antitijelo-lijek konjugat

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2264145T3 (es) * 1995-11-30 2006-12-16 The Board Of Regents, The University Of Texas System Metodos y composiciones para el tratamiento de cancer.
EP1012276A2 (en) * 1997-02-24 2000-06-28 Therion Biologics Corporation Recombinant pox virus for immunization against muc1 tumor-associated antigen
US6228843B1 (en) * 1999-04-23 2001-05-08 University Technology Corporation Method of using PKC inhibiting compounds to treat vascular disease
JP2003510094A (ja) * 1999-09-08 2003-03-18 トランジェーヌ、ソシエテ、アノニム Ｍｕｃ−１由来のペプチド
GB9930359D0 (en) * 1999-12-22 2000-02-09 Glaxo Group Ltd Novel polypeptides
JP2003533181A (ja) * 2000-02-01 2003-11-11 ジ・オースティン・リサーチ・インスティテュート ムチン−１誘導抗原および免疫療法におけるその使用
WO2002062319A2 (en) * 2001-01-19 2002-08-15 Corixa Corporation Microsphere delivery of mucin peptides
US7125663B2 (en) * 2001-06-13 2006-10-24 Millenium Pharmaceuticals, Inc. Genes, compositions, kits and methods for identification, assessment, prevention, and therapy of cervical cancer
US20060069238A1 (en) * 2002-04-15 2006-03-30 Biomira, Inc. Synthetic glyco-lipo-peptides as vaccines
GB0212036D0 (en) * 2002-05-24 2002-07-03 Glaxo Group Ltd Vaccines

Also Published As

Publication number Publication date
MXPA04011527A (es) 2005-09-30
JP2005526520A (ja) 2005-09-08
WO2003100060A3 (en) 2004-02-19
GB0212046D0 (en) 2002-07-03
KR20050004211A (ko) 2005-01-12
NZ536668A (en) 2007-01-26
RU2303069C2 (ru) 2007-07-20
BR0311211A (pt) 2005-03-01
AR039846A1 (es) 2005-03-02
AU2003240729B2 (en) 2007-12-20
RU2004134331A (ru) 2005-08-27
AU2003240729A1 (en) 2003-12-12
US20060251665A1 (en) 2006-11-09
CA2485816A1 (en) 2003-12-04
NO20044947D0 (no) 2004-11-12
TW200407426A (en) 2004-05-16
CN100408682C (zh) 2008-08-06
IS7526A (is) 2004-11-11
CN1668746A (zh) 2005-09-14
ZA200409445B (en) 2006-02-22
IL165156A0 (en) 2005-12-18
WO2003100060A2 (en) 2003-12-04
EP1527177A2 (en) 2005-05-04
PL374569A1 (en) 2005-10-31

Similar Documents

Publication Publication Date Title
Ebensen et al. The bacterial second messenger cyclic diGMP exhibits potent adjuvant properties
RU2583295C2 (ru) Нуклеиновая кислота, содержащая или кодирующая гистоновую структуру типа "стебель-петля" и поли(а)-последовательность или сигнал полиаденилирования, для повышения экспрессии кодируемого белка
BR9712852A (pt) Plasmìdeo, composição, processo de imunização de um indivìduo contra um patógeno, vacina recombinante, patógeno vivo atenuado, proteìna bl-1 substancialmente pura, vetor recombinante de expressão, e, anticorpo isolado
EP2773760B1 (en) Double-stranded rna for immunostimulation
US6090791A (en) Method for inducing mucosal immunity
AU2003263552A1 (en) Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
EP2141227A3 (en) Hyperblebbing bacterial strains and use thereof for production of vaccines
WO2003100060A3 (en) Muc-1 antigen with reduced number of vntr repeat units
FI902569A0 (fi) Producering av till gonorre anslutande pi-proteiner och vaccin.
HUP0302481A2 (hu) Virulencia gének, fehérjék és alkalmazásuk
DE69736276D1 (de) Menschliche dnase resistent gegen actininhibitoren
DE60204317D1 (de) Methode zur plasmidstabilisierung durch in vivo deletion der antibiotikaresistenz und selektion mit einem essentiellen gen
CN103012577B (zh) 一种重组猪白细胞介素4及其编码基因和表达方法
BR9910005A (pt) Composição de vacina, processos para imunização contra neisseria gonorrhoeae e para preparar uma composição de vacina, sequência de dna isolada e purificada, plasmìdeo, célula hospedeira, processo para produção de uma proteìna pilina recombinante quimérica de neisseria gonorrhoeae e neisseria meningitidis, proteìna pilina recombinante quimérica isolada e purificada de neisseria gonorhoeae e neisseria meningitidis, e, processo para imunização contra neisseria muningitidis
WO2002098455A3 (en) Production of recombinant human arylsulfatase a
CN112574997A (zh) 一种fbxw7环状rna的改构体及其在肿瘤药物和新冠疫苗中的应用
BRPI0519330A2 (pt) Ácido nuclÉico isolado; vetor; cÉlula hospedeira; mÉtodo para expressar uma proteÍna; polipeptÍdeo isolado; cromoproteÍna isolada; oligonucleotÍdeo; mÉtodo para identificar um Ácido nuclÉico que codifica uma apoproteÍna de um enediina de nove membros contendo cromoproteÍna; cultura biologicamente pura de actinomadura sp. 21g792 (nrrl 30778); mÉtodo para preparar uma cromoproteÍna; mÉtodo para preparar uma cromoproteÍna modificada; mÉtodo para inibir a progressço de uma doenÇa neoplÁsica em um mamÍfero; composiÇço farmacÊutica; e composto
NO20081541L (no) Ny sjo-lus vaksine
NO20051561L (no) Nukleinsyremolekyler som koder for humant papillomavirus og anvendelse av disse i vaksine.
Wang et al. Role of PG0192 and PG0193 in the modulation of pro‐inflammatory cytokines in macrophages in response to Porphyromonas gingivalis
Madison et al. Partial digestion of a yeast lysine transfer ribonucleic acid and reconstruction of the nucleotide sequence
CN105713916B (zh) 一种铜绿假单胞菌基因及其dna疫苗
Yen et al. Biological activity of ovine IL-23 expressed using a foot-and-mouth disease virus 2A self-cleaving peptide
CN112725378B (zh) 一种人工改造的akt3环状rna及其在新冠疫苗中的应用
CN118812671B (zh) 一种蛋白质、自复制mRNA分子及一种狂犬病毒saRNA疫苗

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application